RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity
25 Feb, 2021 | 08:52h | UTCRelated study: Once-weekly, high-dose semaglutide is effective for improving overweight or obesity among non-diabetic adults – New England Journal of Medicine (study and commentary)
Commentary on Twitter
In this RCT, once-weekly subcutaneous semaglutide used as an adjunct to intensive behavioral therapy & low-calorie diet led significantly greater weight loss vs placebo over 68 weeks among adults w #overweight or #obesity w/o #diabetes https://t.co/xFedvckUUj @PennMedicine #STEP3
— JAMA (@JAMA_current) February 24, 2021